TY - STD TI - China AIDS Response Progress Report. [ebook] National Health and Family Planning Commission of the People’s Republic of China. 2015. http://www.unaids.org/sites/default/files/country/documents/CHN_narrative_report_2015.pdf. Accessed 12 Jul 2018. UR - http://www.unaids.org/sites/default/files/country/documents/CHN_narrative_report_2015.pdf ID - ref1 ER - TY - STD TI - Aidsdatahub.org. China| AIDS data, AIDS Data Download, China Information, China Review. 2018. http://www.aidsdatahub.org/Country-Profiles/China. Accessed 15 Aug 2018. UR - http://www.aidsdatahub.org/Country-Profiles/China ID - ref2 ER - TY - JOUR AU - Zhang, N. AU - Bussell, S. AU - Wang, G. PY - 2016 DA - 2016// TI - Disparities in HIV Care along the path from infection to viral suppression: a cross-sectional study of HIV/AIDS patient records in 2013, Shandong Province, China JO - Clin Infect Dis VL - 63 UR - https://doi.org/10.1093/cid/ciw190 DO - 10.1093/cid/ciw190 ID - Zhang2016 ER - TY - STD TI - WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015.http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/. Accessed 15 Aug 2018. UR - http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/ ID - ref4 ER - TY - STD TI - WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2016. http://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed 15 Aug 2018. UR - http://www.who.int/hiv/pub/arv/arv-2016/en/ ID - ref5 ER - TY - JOUR AU - Chawla, A. AU - Wang, C. AU - Patton, C. PY - 2018 DA - 2018// TI - A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population JO - Infect Dis Ther VL - 7 UR - https://doi.org/10.1007/s40121-018-0201-6 DO - 10.1007/s40121-018-0201-6 ID - Chawla2018 ER - TY - STD TI - WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance. Geneva: World Health Organization; 2018 (WHO/CDS/HIV/18.18). Licence: CC BY-NC-SA 3.0 IGO. 2018. http://www.who.int/hiv/pub/guidelines/ARV2018update/en/. Accessed 15 Aug 2018. UR - http://www.who.int/hiv/pub/guidelines/ARV2018update/en/ ID - ref7 ER - TY - JOUR AU - Clotet, B. AU - Feinberg, J. AU - Lunzen, J. PY - 2014 DA - 2014// TI - Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study JO - Lancet VL - 383 UR - https://doi.org/10.1016/S0140-6736(14)60084-2 DO - 10.1016/S0140-6736(14)60084-2 ID - Clotet2014 ER - TY - JOUR AU - Raffi, F. AU - Rachlis, A. AU - Stellbrink, H. PY - 2013 DA - 2013// TI - Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study JO - Lancet VL - 381 UR - https://doi.org/10.1016/S0140-6736(12)61853-4 DO - 10.1016/S0140-6736(12)61853-4 ID - Raffi2013 ER - TY - JOUR AU - Walmsley, S. AU - Antela, A. AU - Clumeck, N. PY - 2013 DA - 2013// TI - Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1215541 DO - 10.1056/NEJMoa1215541 ID - Walmsley2013 ER - TY - JOUR AU - Patel, D. AU - Snedecor, S. AU - Tang, W. PY - 2014 DA - 2014// TI - 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis JO - PLoS ONE VL - 9 UR - https://doi.org/10.1371/journal.pone.0105653 DO - 10.1371/journal.pone.0105653 ID - Patel2014 ER - TY - JOUR AU - Kanters, S. AU - Socias, M. E. AU - Paton, N. I. AU - Vitoria, M. AU - Doherty, M. AU - Ayers, D. AU - Popoff, E. AU - Chan, K. AU - Cooper, D. A. AU - Wiens, M. O. AU - Calmy, A. AU - Ford, N. AU - Nsanzimana, S. AU - Mills, E. J. PY - 2017 DA - 2017// TI - Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis JO - The Lancet HIV VL - 4 UR - https://doi.org/10.1016/S2352-3018(17)30109-1 DO - 10.1016/S2352-3018(17)30109-1 ID - Kanters2017 ER - TY - JOUR AU - Aboud, M. AU - Kaplan, R. AU - Lombaard, J. AU - Zhang, F. AU - Hidalgo, J. AU - Mamedova, E. PY - 2018 DA - 2018// TI - Week 48 results of a randomised study of dolutegravir versus lopinavir/ritonavir in adults with HIV-1 after failure on first-line therapy JO - Lancet Infect Dis. VL - 19 UR - https://doi.org/10.1016/S1473-3099(19)30036-2 DO - 10.1016/S1473-3099(19)30036-2 ID - Aboud2018 ER - TY - JOUR AU - Tremblay, G. AU - Chounta, V. AU - Piercy, J. PY - 2018 DA - 2018// TI - Cost effectiveness of dolutegravir as a first-line treatment option in the HIV-1-infected treatment-naive patients in Russia JO - Value Health Reg Issues. VL - 16 UR - https://doi.org/10.1016/j.vhri.2018.08.001 DO - 10.1016/j.vhri.2018.08.001 ID - Tremblay2018 ER - TY - JOUR AU - Lifson, A. AU - Krantz, E. AU - Eberly, L. PY - 2011 DA - 2011// TI - Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort JO - AIDS Res Ther. VL - 8 UR - https://doi.org/10.1186/1742-6405-8-2 DO - 10.1186/1742-6405-8-2 ID - Lifson2011 ER - TY - JOUR AU - Mauskopf, J. AU - Brogan, A. AU - Talbird, S. AU - Martin, S. PY - 2012 DA - 2012// TI - Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection JO - AIDS VL - 26 UR - https://doi.org/10.1097/QAD.0b013e32834e87e6 DO - 10.1097/QAD.0b013e32834e87e6 ID - Mauskopf2012 ER - TY - JOUR AU - Lichtenstein, K. AU - Armon, C. AU - Buchacz, K. PY - 2010 DA - 2010// TI - Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study JO - Clin Infect Dis VL - 51 UR - https://doi.org/10.1086/655144 DO - 10.1086/655144 ID - Lichtenstein2010 ER - TY - JOUR AU - d’Arminio Monforte, A. AU - Sabin, C. A. AU - Phillips, A. PY - 2005 DA - 2005// TI - The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy JO - Arch Intern Med VL - 165 UR - https://doi.org/10.1001/archinte.165.4.416 DO - 10.1001/archinte.165.4.416 ID - d’Arminio Monforte2005 ER - TY - JOUR AU - Kimmel, A. D. AU - Goldie, S. J. AU - Walensky, R. P. PY - 2005 DA - 2005// TI - Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients JO - Antivir Ther VL - 10 ID - Kimmel2005 ER - TY - STD TI - GHODR Life tables by Country: China. 2018 http://apps.who.int/gho/data/?theme=main&vid=60340. Accessed 15 Aug 2018. UR - http://apps.who.int/gho/data/?theme=main&vid=60340 ID - ref20 ER - TY - JOUR AU - Franks, P. AU - Hanmer, J. AU - Fryback, D. G. PY - 2006 DA - 2006// TI - Relative disutilities of 47 risk factors and conditions assessed with seven preference-based health status measures in a national US sample: toward consistency in cost-effectiveness analyses JO - Med Care. VL - 1 UR - https://doi.org/10.1097/01.mlr.0000207464.61661.05 DO - 10.1097/01.mlr.0000207464.61661.05 ID - Franks2006 ER - TY - JOUR AU - Paltiel, A. D. AU - Scharfstein, J. A. AU - Seage, G. PY - 1998 DA - 1998// TI - A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection JO - Med Decis Mak. VL - 18 UR - https://doi.org/10.1177/0272989X98018002S11 DO - 10.1177/0272989X98018002S11 ID - Paltiel1998 ER - TY - JOUR AU - Kauf, T. AU - Roskell, N. AU - Shearer, A. PY - 2008 DA - 2008// TI - A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy JO - Value Health VL - 11 UR - https://doi.org/10.1111/j.1524-4733.2008.00326.x DO - 10.1111/j.1524-4733.2008.00326.x ID - Kauf2008 ER - TY - STD TI - Centre of China Government Procurement . Drug Prices. 2018. http://www.ccgp.gov.cn/. Accessed 15 Aug 2018. UR - http://www.ccgp.gov.cn/ ID - ref24 ER - TY - JOUR AU - Yang, H. AU - Li, J. AU - Wu, Z. PY - 2003 DA - 2003// TI - Study on health service utilization and medical expenses for people living with HIV and AIDS JO - Chin J Epidemiolo VL - 24 ID - Yang2003 ER - TY - JOUR AU - Yang, G. AU - Xu, Y. AU - Huang, L. PY - 2015 DA - 2015// TI - Analysis of hospitalization expenses and security status of HIV-infected patients and patients based on HIS system of medical institutions JO - Med Soc VL - 28 ID - Yang2015 ER - TY - JOUR AU - Guo, F. AU - Hsieh, E. AU - Lv, W. PY - 2017 DA - 2017// TI - Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease JO - BMC Infect Dis VL - 17 UR - https://doi.org/10.1186/s12879-017-2358-0 DO - 10.1186/s12879-017-2358-0 ID - Guo2017 ER - TY - JOUR AU - Thirumurthy, H. AU - Chamie, G. AU - Jain, V. PY - 2013 DA - 2013// TI - Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts JO - AIDS VL - 27 UR - https://doi.org/10.1097/QAD.0b013e32835c54d8 DO - 10.1097/QAD.0b013e32835c54d8 ID - Thirumurthy2013 ER - TY - JOUR AU - Zhang, M. AU - Shang, M. AU - Yang, W. PY - 2014 DA - 2014// TI - Treatment effect and drug-resistant mutations in Chinese AIDS patients switching to second-line antiretroviral therapy JO - PLoS ONE VL - 9 UR - https://doi.org/10.1371/journal.pone.0110259 DO - 10.1371/journal.pone.0110259 ID - Zhang2014 ER - TY - JOUR AU - Despiégel, N. AU - Anger, D. AU - Martin, M. PY - 2015 DA - 2015// TI - Cost-effectiveness of dolutegravir in HIV-1 treatment-naive and treatment-experienced patients in Canada JO - Infect Dis Ther VL - 4 UR - https://doi.org/10.1007/s40121-015-0071-0 DO - 10.1007/s40121-015-0071-0 ID - Despiégel2015 ER - TY - JOUR AU - Peng, S. AU - Tafazzoli, A. AU - Dorman, E. PY - 2015 DA - 2015// TI - Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States JO - J Med Econ VL - 18 UR - https://doi.org/10.3111/13696998.2015.1046878 DO - 10.3111/13696998.2015.1046878 ID - Peng2015 ER - TY - JOUR AU - Pialoux, G. AU - Marcelin, A. AU - Despiégel, N. PY - 2015 DA - 2015// TI - Cost-effectiveness of dolutegravir in HIV-1 treatment-experienced (TE) patients in France JO - PLoS ONE VL - 10 UR - https://doi.org/10.1371/journal.pone.0145885 DO - 10.1371/journal.pone.0145885 ID - Pialoux2015 ER - TY - JOUR AU - Pialoux, G. AU - Marcelin, A. AU - Cawston, H. PY - 2017 DA - 2017// TI - Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-naive (TN) patients in France JO - Expert Rev Pharmacoecon Outcomes Res VL - 18 UR - https://doi.org/10.1080/14737167.2017.1359542 DO - 10.1080/14737167.2017.1359542 ID - Pialoux2017 ER - TY - JOUR AU - Restelli, U. AU - Rizzardini, G. AU - Antinori, A. PY - 2017 DA - 2017// TI - Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir + ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment of naive and experienced HIV-positive patients JO - Ther Clin Risk Manag VL - 13 UR - https://doi.org/10.2147/TCRM.S135972 DO - 10.2147/TCRM.S135972 ID - Restelli2017 ER - TY - JOUR AU - Lewden, C. AU - Chene, G. AU - Morlat, P. AU - Raffi, F. AU - Dupon, M. AU - Dellamonica, P. AU - Pellegrin, J. L. AU - Katlama, C. AU - Dabis, F. AU - Leport, C. PY - 2007 DA - 2007// TI - HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population JO - J Acquir Immune Defic Syndr. VL - 46 ID - Lewden2007 ER -